Rekvina Labs

Why is Rekvina Labs Ltd falling/rising?

As of 26-Aug, Rekvina Labs Ltd's stock price is rising to Rs. 46.90, up 1.98%, driven by strong performance over the past week and month, significant investor interest, and trading above key moving averages. The stock has reached a new 52-week high and shows bullish momentum with a notable increase in delivery volume.

As of 26-Aug, Rekvina Labs Ltd's stock price is rising, currently at Rs. 46.90, reflecting an increase of Rs. 0.91 or 1.98%. This upward movement is supported by several key factors. Over the past week, the stock has gained 12.47%, significantly outperforming the Sensex, which only rose by 0.73%. In the last month, the stock has surged by 85.38%, while the Sensex has only increased by 1.86%. <BR><BR>Today, Rekvina Labs reached a new 52-week high of Rs. 46.90 and has been on a consecutive gain streak for the last three days, accumulating a total return of 12.42% during this period. The stock is also trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating strong bullish momentum. Furthermore, there has been a notable increase in investor participation, with delivery volume rising by 81.74% compared to the 5-day average, suggesting heightened interest and confidence among investors. Overall, these factors contribute to the stock's rising price.

Which are the latest news on Rekvina Labs?

Should I buy, sell or hold Rekvina Labs Ltd?

Who are in the management team of Rekvina Labs?

The management team of Rekvina Labs consists of Amit Shah (Director), Mukesh Shah (Director), Vibha Mukesh Shah (Additional Director), and Mahendra Shantilal Dalal (Additional Director).

The management team of Rekvina Labs includes the following individuals:<BR><BR>1. Amit Shah - Director<BR>2. Mukesh Shah - Director<BR>3. Vibha Mukesh Shah - Additional Director<BR>4. Mahendra Shantilal Dalal - Additional Director<BR><BR>If you need more details about their roles or the company, feel free to ask!

What does Rekvina Labs do?

Rekvina Labs Ltd is an Indian micro-cap pharmaceutical company specializing in contract research and manufacturing services. As of June 2026, it reported net sales of 1 Cr and a market cap of INR 20 Cr.

Overview: <BR>Rekvina Labs Ltd is an integrated Indian pharmaceutical company operating in the micro-cap market, specializing in contract research and manufacturing services for pharmaceutical formulations.<BR><BR>History: <BR>Rekvina Labs Limited was incorporated on 1st November 1988. It has evolved from a small domestic company in the mid-1980s to a significant player in the pharmaceutical industry, with the latest quarterly results reporting net sales and profits for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 1 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 20 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.22 <BR>Return on Equity: 25.00% <BR>Price to Book: -20.39 <BR><BR>Contact Details: <BR>Address: 328 Paradise Complex, Sayajigunj Vadodara Gujarat : 390005 <BR>Tel: 91-265-2362966 <BR>Email: rekvina@gmail.com <BR>Website: http://www.rekvinalaboratories.com

Who are the peers of the Rekvina Labs?

Rekvina Labs' peers include Sun Pharma, Divi's Lab, Torrent Pharma, Cipla, Lupin, Dr Reddy's Labs, Cresanto Global, Sang Froid Labs, and Vardhaman Labs. Sun Pharma and Lupin show excellent growth and management quality, while Divi's Lab has the highest 1-year return at 39.27%, and Cipla has the lowest at -6.46%.

Peers: The peers of Rekvina Labs are Sun Pharma.Inds., Divi's Lab., Torrent Pharma, Cipla, Lupin, Dr Reddy's Labs, Cresanto Global, Sang Froid Labs, and Vardhaman Labs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Torrent Pharma, Cipla, Lupin, and Dr Reddy's Labs, while all other peers, including Rekvina Labs, Cresanto Global, Sang Froid Labs, and Vardhaman Labs, do not qualify. Growth is excellent at Sun Pharma.Inds. and Lupin, average at Torrent Pharma and Dr Reddy's Labs, and below average at Divi's Lab. and Cipla, while the rest do not qualify. Excellent capital structure is noted for Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, good for Torrent Pharma and Lupin, and the remaining peers do not qualify.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 39.27%, while Cipla has the lowest at -6.46%, and Rekvina Labs' 1-year return is not available for comparison. Additionally, Dr Reddy's Labs, Cresanto Global, Sang Froid Labs, and Vardhaman Labs have negative six-month returns.

When is the next results date for Rekvina Labs Ltd?

The next results date for Rekvina Labs Ltd is 13 August 2026.

The next results date for Rekvina Labs Ltd is scheduled for 13 August 2026.

Are Rekvina Labs Ltd latest results good or bad?

Rekvina Labs Ltd's latest results show mixed performance, with a 105.71% revenue increase and a 50% reduction in net loss, but ongoing challenges like negative book value and persistent losses raise concerns about its financial stability and profitability. Overall, the outlook remains cautious despite some positive metrics.

Rekvina Labs Ltd's latest results present a mixed picture. On one hand, there has been a notable improvement in certain metrics; for instance, the company reported a revenue of ₹0.72 crores in Q4 FY26, which is a significant sequential growth of 105.71% compared to the previous quarter. Additionally, the net loss has improved by 50% quarter-over-quarter, now standing at ₹0.06 crores. The operating margin has also shown improvement, moving from -34.29% to -8.33%.<BR><BR>However, despite these positive changes, the company continues to face significant challenges. It has a negative book value, meaning its liabilities exceed its assets, which raises serious concerns about its financial health. The persistent net losses and lack of a clear path to profitability indicate ongoing operational difficulties. Moreover, the stock has experienced considerable volatility and has declined significantly over the past month, reflecting growing investor skepticism.<BR><BR>Overall, while there are signs of improvement in revenue and loss reduction, the fundamental issues regarding profitability and financial stability remain a concern, leading to a cautious outlook on the company's performance.